Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347308 | 0.87 | ALDH1A1 (0.51) | MEN1KMT2APOLBALDH1A1HTR1A | |
| SCHEMBL19227456 | 0.84 | POLB (0.71) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL5692621 | 0.84 | POLB (0.56) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL6411154 | 0.83 | MEN1 (0.53) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL17537447 | 0.81 | SYK (0.59) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL14577958 | 0.81 | POLB (0.59) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL3426969 | 0.81 | SYK (0.59) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL14578262 | 0.81 | SYK (0.59) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL22337384 | 0.80 | SYK (0.58) | MEN1KMT2ASYKPOLBNPC1 | |
| SCHEMBL7988768 | 0.80 | MEN1 (0.68) | MEN1KMT2ASYKPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2346837-B1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP (CA) | 2015-03-04 | — | — | EP | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-8114995-B2 | Methods of preparing quinazolinone derivatives | RESVERLOGIX CORP. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114995-B2 | Methods of preparing quinazolinone derivatives | RESVERLOGIX CORP. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2010-01-07 | — | — | US | disclosed |
| WO-2009158404-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | RESVERLOGIX CORP. (CA) | 2009-12-30 | — | — | WO | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | MEN1 1154/4885KMT2A 52/4885SYK 2594/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MEN1 4390/4885KMT2A 3772/4885SYK 3892/4885 |
| US-20100004448-A1 | METHODS OF PREPARING QUINAZOLINONE DERIVATIVES | APOB, APOL1, LDLR | MEN1 4635/4885KMT2A 3722/4885SYK 4616/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | MEN1 4262/4885KMT2A 1735/4885SYK 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.